

# Multiple scaly plaques on the head and arm

**LAXMI IYENGAR** BSc(Hons), MB BS, PhD, FRACGP

**ALVIN H. CHONG** MB BS, MMed, FACD

Test your diagnostic skills in our regular dermatology quiz. What is the cause of these scaly plaques on a background of chronically sun-damaged skin?

## Case presentation

An 80-year-old Caucasian man presents for his annual full skin examination. He has scaly plaques over sun-exposed areas, including his head (Figures 1a and b) and arm (Figure 2). There is no tenderness or itch associated with the lesions.

The patient had a squamous cell carcinoma excised from his scalp two years previously. He has no history of immunocompromise or use of photosensitising medications. He denies a family history of melanoma or other skin cancer.

The patient is otherwise well and taking no regular medications. Before retirement, he worked as a builder and he still enjoys playing golf.

On examination, multiple scaly plaques are observed on the right side of the patient's face and the dorsum of his right hand and forearm. A background of sun-damaged skin is noted. There is no associated cervical, axillary or inguinal lymphadenopathy. He has Fitzpatrick skin type 2.

MedicineToday 2024; 25(11): 71-73

Dr Iyengar is Education Fellow at the Skin Health Institute, Melbourne, and a GP in private practice. Adjunct Associate Professor Chong is a Dermatologist at St Vincent's Hospital, Melbourne, and Head of the Transplant Dermatology Clinic at Skin Health Institute, Melbourne. He is also the producer of the 'Spot Diagnosis' podcast series ([spotdiagnosis.org.au](https://spotdiagnosis.org.au)) provided by the Skin Health Institute, Melbourne, Vic.



**Figures 1a and b.** The case patient at presentation, with multiple erythematous, scaly plaques visible on the right side of his forehead (above) and ear (right).

Images published with patient consent.



## Differential diagnoses

Conditions to consider among the differential diagnoses include the following.

### Squamous cell carcinoma in situ

Squamous cell carcinoma (SCC) in situ, which is also known as intraepidermal SCC or Bowen's disease, is considered to be a premalignant lesion. If left untreated, it has the capacity to progress to an invasive malignancy; however, this is rare (published rates are between 3% and 5%).<sup>1</sup> SCC in situ presents as a plaque that is red, scaly and crusty and often asymptomatic.

Sun-exposed areas, such as the upper or lower limbs, are typical locations. A skin biopsy may be needed to establish a diagnosis.

### Cutaneous squamous cell carcinoma

Cutaneous SCC (cSCC) occurs when dysplastic squamous cells invade the dermis. They typically present as progressively enlarging hyperkeratotic nodules that can be tender or indurated and are often ulcerated. The diagnosis is usually clinical and can be confirmed by biopsy. High-risk SCCs include lesions that are located



**Figure 2.** Lesions on the right forearm and hand (case patient).

Image published with patient consent.

on mucosal surfaces, such as the lips or genitalia, as these have a strong propensity to metastasise, particularly in patients who are immunosuppressed.<sup>2,3</sup>

### Superficial basal cell carcinoma

Basal cell carcinoma (BCC) is the most common cancer arising from the basal cells of the epidermis. Clinically, a superficial BCC can resemble an SCC in situ as a small

erythematous plaque with associated ulceration; however, a BCC may have a visible shine over its surface. Superficial BCCs tend to ulcerate and are not usually scaly. They tend to be locally invasive but metastasis is rare.

### Nodular basal cell carcinoma

A nodular BCC typically presents as a slow-growing, pearly, elevated nodule that

can bleed and ulcerate centrally and has a surrounding fleshy, shiny rim. They commonly arise on the face, particularly on the nose or near the eyelids, and are usually solitary. Arborising telangiectasia can be noted on dermoscopic examination, which is pathognomonic for BCC.

### Seborrhoeic keratosis

Seborrhoeic keratosis is a common benign cutaneous eruption associated with increasing age, the cause for which is unknown. The clinical presentation can vary but they often occur as a warty solitary plaque or as a papule. The hallmarks of seborrhoeic keratoses include fissures, furrows forming a cerebriform pattern, white milia-like cysts and comedo-like openings, which can all be visualised on dermoscopy.

### Actinic keratosis

This is the correct diagnosis. Actinic keratosis (AK), also known as solar keratosis, is a lesion that manifests following cumulative exposure to UV radiation, which causes irreversible DNA damage within keratinocytes. Australia has the highest prevalence of AK, where it is estimated to affect more than 40% of adults over the age of 40 years.<sup>4,5</sup> Risk is increased for Caucasian people (Fitzpatrick skin type 1 and 2) and people who live in close proximity to equatorial regions, where there is greater exposure to UV radiation.<sup>6</sup> Increasing age, male sex, immunocompromise, photosensitising drugs (e.g. azathioprine) and occupational exposure to arsenic are other risk factors. Solid organ transplant recipients are up to 250 times more likely to develop AK.<sup>7</sup>

AK has a predilection for sun-exposed areas of skin. Commonly affected sites include the face (particularly the nose), the upper and lower limbs, including the dorsum of the hands and feet, and the scalp in bald men.

The clinical appearance of AKs can vary significantly, both within and between individuals, often making this common condition a challenging diagnosis.<sup>8</sup> Clinically, AK can present as a macule or a

## MEDICAL THERAPIES FOR ACTINIC KERATOSIS

### 5-Fluorouracil

5-Fluorouracil (5-FU) is a chemotherapeutic agent that has a cytotoxic effect on actinic skin, with efficacy dependent on the degree of inflammation, erosion and ulceration elicited. In a randomised control trial, a single two- to four-week course of topical 5-FU showed effective chemoprevention of cutaneous squamous cell carcinoma for one year.<sup>13</sup>

5-FU is available in two cream formulations: a 5% strength (applied once or twice daily) and newer 4% strength (applied once daily). The use of twice daily 5% 5-FU or once daily 4% 5-FU cream has demonstrated similar rates for complete clearance of actinic keratosis (AK), with the 4% cream showing superior tolerability.<sup>14</sup> The 4% cream, which is indicated for the treatment of AK of the face, ears and/or scalp, is applied for a period of four weeks, as tolerated. The 5% cream is usually applied for three to four weeks.

A liquid solution of 0.5% 5-FU in combination with 10% salicylic acid is available, which is indicated for targeted lesion and/or small-field therapy. It is applied once daily for up to 12 weeks.

Combination treatment of 5-FU plus calcipotriol has been described as being effective.<sup>15</sup> However, this is not routinely used in Australia as calcipotriol is not PBS listed.

Patients need to be counselled about the expected inflammatory response to 5-FU. Common side effects include soreness and pain at the site of application, itchiness or irritation, darkening or reddening of the skin, burning, crusting, increased photosensitivity and scarring. To improve tolerability, patients are usually advised to treat one anatomical segment at a time (e.g. first the forehead and temples, then cheeks and nose, then quadrants of the scalp and ears), often during winter when sun exposure is more easily avoided.

### Imiquimod

Imiquimod 5% cream is a topical immunomodifying field treatment. It promotes the secretion of proinflammatory cytokines, which in turn stimulate the host immune response to induce apoptosis in precancerous cells in AK.

Imiquimod is available in a 5% cream formulation. For the treatment of AK, it is generally applied three times per week for up to four weeks initially followed by a treatment-free period (cyclical regimen), or up to 16 weeks (continuous regimen).<sup>11,12,16</sup> It has a similar side effect profile to 5-FU but is less cost effective. The treatment is usually applied directly to actinic skin, covering a small area of the face at a time to improve tolerability. It is generally left on overnight for approximately eight hours and washed off with water afterwards.

### Photodynamic therapy

Photodynamic therapy (PDT) is a two-step process for destroying precancerous cells that involves applying a photosensitising chemical to actinic skin and then exposing the treated area to light. Daylight PDT utilising methyl aminolevulinate (MAL) is an efficacious field treatment for AK, especially for large areas of chronic actinic damage, and is generally well tolerated.<sup>17</sup> Conventional PDT, which utilises 5-aminolevulinic acid or MAL as a photosensitising agent and a source of red light, can be difficult to access in Australia.

### Diclofenac sodium

Diclofenac sodium 3% gel (in 2.5% hyaluronic acid) is a topical NSAID that can be used for AK treatment. It is applied twice daily for up to three months.<sup>18</sup> This treatment has limited use in clinical practice due to poor efficacy compared with the treatments discussed above.

hyperkeratotic palpable plaque or papule on a background of normal skin or on skin that has a confluent erythematous appearance due to chronic sun damage. There is variation in the colour of AKs – lesions can be flesh-coloured, inflamed or erythematous or, rarely, associated with pigment.<sup>9</sup> The consistency of the lesions can also vary, being associated with a slight scale, often resembling a wart in appearance.

Clinically, there is thought to be a continuum between actinic keratosis, SCC in situ and cSCC; however, progression is uncommon. The risk of malignant transformation of AK to SCC within one year is reported to be less than 1 in 1000.<sup>10</sup> Untreated, the majority of AKs remain stable or regress.<sup>9,10</sup> On examination, SCC in situ tend to be more plaque-like and prone to bleeding than AKs. Tenderness is uncommon for AK but cSCC are often tender.

### Management

Evidence-based treatment for AK is informed by Cancer Council Australia's *Clinical Practice Guidelines for Keratinocyte Cancer* and the American Academy of Dermatology's *Guidelines of Care for the Management of Actinic Keratosis*.<sup>11,12</sup> Both physical and medical therapies are used

to treat AK. The main goals are to treat symptoms and to improve cosmesis.

Cryotherapy, ideally with a liquid nitrogen spray, is a practical and efficient treatment option for AK.<sup>12</sup> It is important to note that lesions will recur as a rule. Routine excision of AK is not generally recommended.

Medical therapies for AK are listed in the Box.<sup>11-18</sup> For patients whose lesions are widespread and resistant to previous treatment, a field therapy will be the treatment of choice. Addition of a keratolytic agent (e.g. 10% salicylic acid) can improve penetration.

In addition, patients should be counselled about the need for sun protection. This includes wearing long-sleeved, dark-coloured clothing with a close weave and broad-brimmed hats and applying sunscreen. Patients should be informed that regular use of sunscreen not only prevents the development of AK, but also enhances the remission of existing lesions.<sup>19</sup>

### Outcome

For the case patient, the diagnosis of AK is consistent with his history of significant cumulative sun exposure. He recalls blistering sunburns as a child growing up in Victoria, and he had an outdoor occupation

and sporting hobby. At the time of this presentation, his AKs had been treated with cryotherapy over a period of years, but the lesions were recurring and increasing in number.

As the patient's AKs were resistant to previous cryotherapy and he had widespread actinic damage, a field therapy was selected. He commenced treatment with 5% 5-fluorouracil, to be applied once daily for four weeks during the winter months, and advised to treat one area at a time (first the forehead and temples, then the cheeks and nose, then the quadrants of the scalp and ears, and then the right hand and arm), to eventually cover all areas of concern. He was counselled about the expected inflammatory response and need to avoid sunlight exposure because of the photosensitising nature of the cream. He was also given advice about sun protection, including the regular use of SPF50+ sunscreen, to optimise his clinical response, and encouraged to continue his annual skin-cancer surveillance. **MT**

### References

A list of references is included in the online version of this article ([www.medicinetoday.com.au](http://www.medicinetoday.com.au)).

COMPETING INTERESTS: None.

# Multiple scaly plaques on the head and arm

**LAXMI IYENGAR** BSc(Hons), MBBS, PhD, FRACGP

**ALVIN H. CHONG** MBBS, MMed, FACD

## References

1. Tokez S, Alblas M, Nijsten T, Pardo LM, Wakkee M. Predicting keratinocyte carcinoma in patients with actinic keratosis: development and internal validation of a multivariable risk-prediction model. *Br J Dermatol* 2020; 183: 495-502.
2. Wheller L, Soyer HP. Clinical features of actinic keratoses and early squamous cell carcinoma. *Curr Probl Dermatol* 2015; 46: 58-63.
3. Rowe DE, Carroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip: implications for treatment modality selection. *J Am Acad Dermatol* 1992; 26: 976-990.
4. Marks R. Epidemiology of non-melanoma skin cancer and solar keratoses in Australia: a tale of self-immolation in Elysian fields. *Australas J Dermatol* 1997; 38 Suppl 1: S26-S29.
5. Chetty P, Choi F, Mitchell T. Primary care review of actinic keratosis and its therapeutic options: a global perspective. *Dermatol Ther (Heidelb)* 2015; 5: 19-35.
6. Chia A, Moreno G, Lim A, Shumack S. Actinic keratoses. *Aust Fam Physician* 2007; 36: 539-543.
7. Euvrard S, Kanitakis J, Pouteil-Noble C, et al. Comparative epidemiologic study on premalignant and malignant epithelial cutaneous lesions developing after kidney and heart transplantation. *J Am Acad Dermatol* 1995; 33(2 Pt 1): 222-229.
8. Rosen T, Lebwahl MG. Prevalence and awareness of actinic keratosis: barriers and opportunities. *J Am Acad Dermatol* 2013; 68(1 Suppl 1): S2-S9.
9. Moy RL. Clinical presentation of actinic keratoses and squamous cell carcinoma. *J Am Acad Dermatol* 2000; 42(1 Pt 2): S8-10.
10. Marks R, Foley P, Goodman G, Hage BH, Selwood TS. Spontaneous remission of solar keratosis: the case for conservative management. *Br J Dermatol* 1986; 115: 649-655.
11. Cancer Council Australia. Clinical practice guidelines for keratinocyte cancer v1.4. Sydney: Cancer Council Australia; 2024. Available online at: <https://www.cancer.org.au/clinical-guidelines/skin-cancer/keratinocyte-cancer> (accessed October 2024).
12. Eisen DB, Asgari MM, Bennett DD, et al. Guidelines of care for the management of actinic keratosis. *J Am Acad Dermatol* 2021; 85: e209-233.
13. Weinstock MA, Thwin SS, Siegel JA, et al. Chemoprevention of basal and squamous cell carcinoma with a single course of fluorouracil, 5%, cream: a randomized clinical trial. *JAMA Dermatol* 2018; 154: 167-174.
14. Dohil MA. Efficacy, safety, and tolerability of 4% 5-fluorouracil cream in a novel patented aqueous cream containing peanut oil once daily compared with 5% 5-fluorouracil cream twice daily: meeting the challenge in the treatment of actinic keratosis. *J Drugs Dermatol* 2016; 15: 1218-1224.
15. Mohney L, Singh R, Grada A, Feldman S. Use of topical calcipotriol plus 5-fluorouracil in the treatment of actinic keratosis: a systematic review. *J Drugs Dermatol* 2022; 21: 60-65.
16. Chen K, Yap LM, Marks R, Shumack S. Short-course therapy with imiquimod 5% cream for solar keratoses: a randomized controlled trial. *Australas J Dermatol* 2003; 44: 250-255.
17. See J-A, Shumack S, Murrell DF, et al. Consensus recommendations on the use of daylight photodynamic therapy with methyl aminolevinate cream for actinic keratosis in Australia. *Australas J Dermatol* 2016; 57: 167-174.
18. Nelson C, Rigel D, Smith S, Swanson N, Wolf J. Phase IV, open-label assessment of the treatment of actinic keratosis with 3.0% diclofenac sodium topical gel (Solaraze). *J Drugs Dermatol* 2004; 3: 401-407.
19. Thompson SC, Jolley D, Marks R. Reduction of solar keratoses by regular sunscreen use. *N Engl J Med* 1993; 329: 1147-1151.